Wall Street is positive on Atea Pharmaceuticals Inc (AVIR). On average, analysts give Atea Pharmaceuticals Inc a Buy rating. The average price target is $13.666, which means analysts expect the stock to climb by 73.87% over the next twelve months. That average ranking earns Atea Pharmaceuticals Inc an Analyst Rating of 16, which is better than 16% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating AVIR a Buy today. Find out what this means to you and get the rest of the rankings on AVIR!